How to Standardize Audit Risks and Legal Exposure Management Across Global Markets

Effective audit risks and legal exposure management are critical components for compliance in the pharmaceutical and biotechnology sectors. Given the complexity of controlling substances across different jurisdictions, regulatory affairs teams must navigate a multitude of regulations, guidelines, and expectations to ensure compliance and optimize operational efficiencies. This guide seeks to provide an in-depth exploration of these regulatory frameworks and practical considerations necessary for maintaining compliance with controlled substances.

Context

The landscape of controlled substances compliance is inherently complex, shaped by various international and national regulations. All pharmaceutical and biotech companies must ensure that they are compliant with the appropriate guidelines when dealing with controlled substances. This includes not only the classification and registration of these substances but also their documentation, distribution, and monitoring. Different regions, including the US, EU, and UK, have their own regulatory frameworks which often intersect yet maintain unique compliance requirements.

Legal/Regulatory Basis

The foundation of controlled substances compliance is rooted in several key regulations across different jurisdictions:

• United States: The Controlled Substances Act (CSA) governs the scheduling and management of controlled substances under the Drug Enforcement Administration (DEA). Compliance with 21 CFR is critical, particularly in Part 1301-1316, which outlines registration, record-keeping, and security requirements.
• European Union: The EU Drugs Directive (2001/83/EC) and corresponding national laws lay out the guidelines for the manufacture, importation, distribution, and control of medicinal products, including controlled substances. Additionally, the EU’s General Data Protection Regulation (GDPR) has implications for data handling in compliance processes.
• United Kingdom: Post-Brexit regulatory measures have shifted some compliance landscapes, with the Misuse of Drugs Act 1971 governing controlled substances. The UK Home Office regulates scheduling, classification, and the issuing of licenses for handling controlled substances.

Documentation Requirements

Documentation is pivotal in demonstrating compliance with regulatory expectations during audits and inspections. Companies must establish comprehensive documentation practices that comply with the specific requirements of each jurisdiction. Key documentation includes:

Regulatory Submissions

Any new controlled substance or significant changes to existing substances may necessitate different types of filings, including:

• New Drug Applications (NDA): Required for new controlled substances.
• Abbreviated New Drug Applications (ANDA): For generics of controlled substances.
• Investigational New Drug Applications (IND): Required for controlled substances in clinical trials.

Record Keeping

Develop robust record-keeping practices that deliver compliance with the documented regulation approach:

• Inventory records must reflect the true quantity of controlled substances on hand.
• Documentation related to the manufacturing processes must be available for review.
• Transaction records, including distribution, must be retained for specified time frames depending on jurisdictional requirements.

Review/Approval Flow

The journey to achieving compliance with controlled substances regulations typically encompasses several review and approval stages.

Pre-Submission Strategies

Prior to submission, companies should engage in thorough internal audits to ascertain potential deficiencies or compliance gaps. It is helpful to adopt a “submission strategy” that includes:

• Initial risk assessments to identify potential audit risks.
• Gap analyses to compare existing practices with regulatory requirements.
• Internal reviews that engage cross-functional teams, including Quality Assurance (QA) and Clinical teams.

Submissions and Agency Interactions

Upon submission, companies will typically experience one of several agency interaction scenarios:

• Priority review timelines for controlled substances that address an unmet medical need.
• Standard review timelines based on the complexity and novelty of the controlled substance.
• Engagement from regulatory agencies for clarification or additional information as part of the review process.

Common Deficiencies and Challenges

While navigating compliance requirements, several common deficiencies often arise that can hinder the approval process or expose companies to regulatory risks:

Documentation Gaps

Failure to provide adequate documentation can significantly delay approvals and may raise red flags during inspections. Key deficiencies include:

• Inadequate record-keeping that fails to demonstrate the traceability of controlled substances.
• Insufficient justification for data that does not meet the bridging data requirements.
• Missing evidence of compliance with internal security controls and monitoring systems.

Non-Compliance with Security Controls

Agencies often scrutinize the security controls implemented in the handling of controlled substances. Common issues include:

• Lack of physical and digital protection measures to safeguard substances.
• Inconsistent employee training on security protocols.
• Unclear chain-of-custody documentation.

Insufficient Risk Management Strategies

Deficient risk management strategies can lead to serious legal repercussions. Companies must be able to:

• Identify areas where exposure could occur and develop proactive risk mitigation plans.
• Maintain transparency in audit trails.
• Document incident responses for any deviations or violations.

RA-Specific Decision Points

Regulatory affairs professionals must navigate specific decision points effectively to ensure compliance and optimize approval timelines.

Variation vs. New Application

Understanding the distinctions between filing a variation and a new application is imperative. Key considerations include:

• A variation would be appropriate for minor changes that do not significantly alter the substance’s profile (e.g., new manufacturing site, changes in the formulation).
• A new application is warranted when substantial changes are made that significantly alter the product, its indications, or its overall disposition.
• Consult relevant EMA guidelines for further clarification on when to pursue variations.

Justifying Bridging Data

Bridging data are critical when applying for approval of a new chemical entity (NCE), especially for controlled substances. Companies should consider:

• Presenting robust preclinical and clinical evidence that supports the therapeutic benefit and safety profile of the NCE.
• Consulting experts in pharmacovigilance (PV) to characterize the safety profile effectively during the submission process.
• Supporting data with well-structured comparative analysis to existing registered controlled substances.

Conclusion

Efficient audit risks and legal exposure management are essential in the realm of controlled substances compliance. By adhering to regulatory guidelines and ensuring comprehensive documentation practices, companies can mitigate risks and enhance their operational readiness during regulatory assessments. Continuous training and collaboration across regulatory affairs, CMC, clinical, and QA teams can further facilitate graceful interactions with regulatory agencies, ultimately leading to smoother approval pathways.

For additional information on regulatory compliance, consider visiting the FDA for US regulations, the EMA for EU guidelines, and the UK Home Office for insights into controlled substances management.